您的位置: 专家智库 > >

国家自然科学基金(30660055)

作品数:2 被引量:7H指数:2
相关作者:郑少萍郑少江郭峻莉罗志飞更多>>
相关机构:华中科技大学海南医学院更多>>
发文基金:国家自然科学基金海南省自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 2篇中文期刊文章

领域

  • 2篇医药卫生

主题

  • 2篇FGFR-1
  • 1篇蛋白质疫苗
  • 1篇血管
  • 1篇血管生成
  • 1篇肿瘤
  • 1篇肿瘤血管
  • 1篇肿瘤血管生成
  • 1篇瘤血管
  • 1篇HIC
  • 1篇FIBROS...
  • 1篇IMMUNO...
  • 1篇ANTI-A...
  • 1篇VACCIN...

机构

  • 1篇华中科技大学
  • 1篇海南医学院

作者

  • 1篇罗志飞
  • 1篇郭峻莉
  • 1篇郑少江
  • 1篇郑少萍

传媒

  • 1篇海南医学院学...
  • 1篇Journa...

年份

  • 1篇2009
  • 1篇2007
2 条 记 录,以下是 1-2
排序方式:
Ag43/FGFR-1嵌合蛋白疫苗抗小鼠纤维肉瘤血管生成的实验研究被引量:4
2009年
目的:利用Antigen43(Ag43)/成纤维细胞生长因子Ⅰ型受体(FGFR-1)重组嵌合蛋白作为疫苗,了解其是否具有抑制小鼠肿瘤生长的作用,并初步探讨其作用机理。方法:40只BALB/c雌性小鼠接种Meth A细胞后第7天,随机分为Ag43/FGFR-1蛋白免疫组(AF组)、Ag43蛋白免疫组(Ag43组)、FGFR-1蛋白免疫组(FGFR-1组)和生理盐水对照组(NS组)4组,每组10只,观察免疫治疗后的荷瘤小鼠肿瘤体积和生存曲线,分别用免疫组织化学方法检测肿瘤组织微血管密度(MVD),免疫印迹(W est-ern blot)方法检测抗自身FGFR-1的抗体,酶联免疫斑点试验(ELISPOT)检测分泌抗自身FGFR-1抗体的B淋巴细胞的数量。结果:Ag43/FGFR-1组与FGFR-1蛋白、Ag43蛋白、生理盐水对照组肿瘤组织MVD计数分别为11.9±2.3、59.6±3.8、60.6±1.2和61.9±3.4(P<0.01);与对照组相比,Ag43/FGFR-1组肿瘤体积明显变小(P<0.01),存活时间明显延长(P<0.01),血清中发现含有抗自身FGFR-1的抗体且发现小鼠脾脏中分泌抗自身FGFR-1抗体的B淋巴细胞数目明显增多(P(0.01)。结论:Ag43/FGFR-1蛋白质疫苗能够诱导荷瘤鼠产生特异性免疫反应,从而抑制肿瘤血管生成和肿瘤的生长。
郭峻莉郑少江郑少萍罗志飞
关键词:蛋白质疫苗肿瘤血管生成
Anti-angiogeneic Target Therapy for Cancer with Vaccine Based on the Recombinant Chicken FGFR-1 in Tumor-bearing Mice被引量:3
2007年
To explore the anti-tumor effect of immunotherapy with recombinant protein vaccine based on FGFR-1 of chicken (cFR-1) in a mouse Meth A fibrosarcoma model, tumor volume and survival rate of the mice were observed at a 3-day interval. Microvessel density (MVD) was detected by immunohistochemistry. Auto-antibodies against self-FGFR-1 were detected by Western blotting and ELISA, respectively. The anti-FGFR-1 antibody-producing B cells (APBCs) were detected by enzyme-linked immunospot (ELISPOT) assay. Eighteen days after inoculation of tumor cells, the tumor volume was significantly smaller in cFR-l-immunized group than in mouse FGFR-1 (mFR-1) immunized group and normal saline (NS) control group (P〈0.05), and the survival time was significantly longer in cFR-l-immunized group than in the control groups (P〈0.01). MVD was significantly lower in cFR-l-immunized group than in mFR-1-immunized group and NS group (16.8 ±5.6 vs 64.6±1.8 and 59.6±8.7, P〈0.01). Antibodies against self-FGFR-1 were found in mFR-1-immunized group, the major antibody subclasses were IgG1 and IgG2b. Compared with the two control groups, the numbers of APBCs in cFR-l-immunized group were significantly increased (P〈0.01) These results demonstrated that the cFR-1-related anti-angiogenesis protein vaccine could induce the production of auto-antibodies against self-FGFR-1, which futher inhibit angiogenesis and growth of solid tumor.
郑少萍张俊志郑少江黄风迎吴人亮曹利民谢明星
关键词:VACCINEANTI-ANGIOGENESISFIBROSARCOMAIMMUNOTHERAPY
共1页<1>
聚类工具0